Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC118 + Toripalimab/RC148 in CLDN18.2+ Solid Tumors
NCT06038396Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Aug 2023
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of RC118 in solid tumor, gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Aug 2023; status: recruiting.
02
Drugs
RC118
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06038396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038396.